clinical trial

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)

Authors: Neal D. Shore, Daniel Saltzstein, Paul Sieber, Bryan Mehlhaff, Lawrence Gervasi, Jennifer Phillips, Yu-Ning Wong, Huiling Pei, Tracy McGowan

Journal: Clinical Genitourinary Cancer

Year Published: 2019

Background: The objective of this study was to evaluate differences in tolerability in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P). Patients and Methods: This was a phase […]

A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder

Authors: G. I. Papakostas, K. Johe, H. Hand, A. Drouillard, P. Russo, G. Kay, R. Kashambwa, B. Hoeppner, M. Flynn, A. Yeung, M. A. Martinson & M. Fava

Journal: Molecular Psychiatry

Year Published: 2019

NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways. This trial evaluated oral NSI-189 as monotherapy in major depressive disorder. To improve signal detection, the sequential-parallel comparison design (SPCD) was chosen. Two hundred and […]

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia

Authors: Akihiro Shiina, Nobuhisa Kanahara, Tsuyoshi Sasaki, Yasunori Oda, Tasuku Hashimoto, Tadashi Hasegawa, Taisuke Yoshida, Masaomi Iyo, Kenji Hashimoto

Journal: Clinical Psychopharmacology and Neuroscience

Year Published: 2015

Objective: Schizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant […]

1 2

Back to Publications